Floatz logo

ima950

Oligoastrocytoma, Mixed

Nicholas ButowskivaccinePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Oligoastrocytoma, Mixed cohort.

Asset / SponsorPhaseRating
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 1/2BB
CHLOROTOXIN
TransMolecular
Phase 2CCC
ETOPOSIDE
Washington University School of Medicine
Phase 2CCC
Inno-206
Washington University School of Medicine
Phase 2CCC
Irinotecan
Washington University School of Medicine
Phase 1CC

View all 12 →

Same molecule, other indications

ima950 is also rated in:

central nervous system neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
central nervous system neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
adult glioblastomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →